pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
PFIZER · news · pharmadog
← back to PFIZER
News mentioning PFIZER
192
stories
20h
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
1d
Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
biospace
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
3d
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
6d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
6d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
6d
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
8d
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
fiercebiotech
8d
Post-Hoc: Rewatch the Boston edition of our China Biotech Debate
endpoints
8d
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
9d
CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaques
fiercebiotech
9d
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
biopharma dive
10d
BMS picks Texas for new $2.3B manufacturing campus
biospace
12d
Is China’s work ethic a ‘wake-up call’?; The megamerger that wasn’t; and more
endpoints
13d
STAT+: Up and down the ladder: The latest comings and goings
stat
13d
China biotech will slow as it nears R&D frontier, Pfizer’s Baum predicts
endpoints
13d
STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more
stat
14d
STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts
stat
14d
STAT+: Pharmalittle: We’re reading about Moderna’s flu shot, a death in a gene-editing trial in China, and more
stat
15d
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
15d
STAT+: Could poop pills be the next treatment for food allergies?
stat
15d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
15d
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
15d
STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
stat
15d
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
16d
Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
biospace
16d
Pfizer has already made its biggest deals, Bourla says
endpoints
16d
Pfizer expands multibillion-dollar cost-cutting plan
biopharma dive
16d
STAT+: Three biotechs with three news updates
stat
16d
BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine
biospace
← prev
page 1 of 7
next →
